Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H2 2016

Global Markets Direct’s, ‘Chronic Obstructive Pulmonary Disease (COPD) – Pipeline Review, H2 2016’, provides an overview of the Chronic Obstructive Pulmonary Disease (COPD) pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Chronic Obstructive Pulmonary Disease (COPD) and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

The report provides a snapshot of the global therapeutic landscape of Chronic Obstructive Pulmonary Disease (COPD)

The report reviews pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD) by companies and universities/research institutes based on information derived from company and industry-specific sources

The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

The report reviews key players involved Chronic Obstructive Pulmonary Disease (COPD) therapeutics and enlists all their major and minor projects

The report assesses Chronic Obstructive Pulmonary Disease (COPD) therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

The report summarizes all the dormant and discontinued pipeline projects

The report reviews latest news related to pipeline therapeutics for Chronic Obstructive Pulmonary Disease (COPD)

Reasons to buy

Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

Identify and understand important and diverse types of therapeutics under development for Chronic Obstructive Pulmonary Disease (COPD)

Identify potential new clients or partners in the target demographic

Develop strategic initiatives by understanding the focus areas of leading companies

Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

Devise corrective measures for pipeline projects by understanding Chronic Obstructive Pulmonary Disease (COPD) pipeline depth and focus of Indication therapeutics

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

AB2 Bio Ltd.

Abeona Therapeutics, Inc.

Ache Laboratorios Farmaceuticos S/A

Achillion Pharmaceuticals, Inc.

Adamis Pharmaceuticals Corporation

Advinus Therapeutics Ltd

AlgiPharma AS

Allinky Biopharma

Alteogen Inc.

Amakem NV

Ampio Pharmaceuticals, Inc.

Angion Biomedica Corp.

Apellis Pharmaceuticals Inc

Aridis Pharmaceuticals LLC

Astellas Pharma Inc.

AstraZeneca Plc

Asubio Pharma Co., Ltd.

Axikin Pharmaceuticals, Inc.

Bayer AG

Beech Tree Labs, Inc.

Bioneer Corporation

Biotie Therapies Corp.

Boehringer Ingelheim GmbH

C4X Discovery Holdings PLC

Carolus Therapeutics, Inc.

Cellular Biomedicine Group, Inc.

Chiesi Farmaceutici SpA

Circassia Pharmaceuticals Plc

CSL Limited

Cytokinetics, Inc.

Daiichi Sankyo Company, Limited

Diffusion Pharmaceuticals Inc.

Domainex Limited

Elsalys Biotech SAS

enGene, Inc

Errant Gene Therapeutics, LLC

F. Hoffmann-La Roche Ltd.

Foresee Pharmaceuticals, LLC

Galapagos NV

Gilead Sciences, Inc.

GlaxoSmithKline Plc

Hanmi Pharmaceuticals, Co. Ltd.

iCeutica, Inc.

InMed Pharmaceuticals Inc.

Innate Pharma S.A.

INVENT Pharmaceuticals, Inc.

Invion Limited

Jiangsu Hansoh Pharmaceutical Co., Ltd.

Johnson & Johnson

KaloBios Pharmaceuticals, Inc.

Kissei Pharmaceutical Co., Ltd.

Kyowa Hakko Kirin Co., Ltd.

Ligand Pharmaceuticals, Inc.

Medestea Research & Production S.p.A.

Merck & Co., Inc.

Mereo Biopharma Group Plc

Meridigen Biotech Co., Ltd.

Microbion Corporation

Novartis AG

Odan Laboratories Ltd.

OPKO Health, Inc.

Orion Oyj

Panmira Pharmaceuticals, LLC.

Pfizer Inc.

PharmaLundensis AB

Pharmaxis Limited

Pila Pharma AB

Polyphor Ltd.

Promedior, Inc.

ProMetic Life Sciences Inc.

Proteostasis Therapeutics, Inc.

Pulmagen Therapeutics LLP

Pulmatrix, Inc.

Quark Pharmaceuticals, Inc.

Re-Pharm Limited

Recipharm AB

Respira Therapeutics Inc

Respiratorius AB

rEVO Biologics, Inc.

Rhizen Pharmaceuticals S.A.

SATT North SAS

Selvita S.A.

Seoul Pharma Co., Ltd.

Spring Bank Pharmaceuticals, Inc.

Stelic Institute & Co., Inc.

sterna biologicals Gmbh & Co KG

Sucampo Pharmaceuticals, Inc.

Sun Pharma Advanced Research Company Ltd.

Sunovion Pharmaceuticals Inc.

Synovo GmbH

Syntrix Biosystems, Inc.

Takeda Pharmaceutical Company Limited

Teva Pharmaceutical Industries Ltd.

TGV-Laboratories

Therabron Therapeutics, Inc.

Theravance Biopharma, Inc.

Torrent Pharmaceuticals Limited

U.S. Stem Cell, Inc.

Unizyme Laboratories A/S

Vectura Group Plc

Verona Pharma Plc

Vertex Pharmaceuticals Incorporated

Yuhan Corporation

Yungjin Pharm. Co., Ltd.

Zambon Company S.p.A.

Table of Contents

Table of Contents

Table of Contents 2

Introduction 8

Chronic Obstructive Pulmonary Disease (COPD) Overview 9

Therapeutics Development 10

Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Development by Companies 12

Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics under Investigation by Universities/Institutes 22

Chronic Obstructive Pulmonary Disease (COPD) - Pipeline Products Glance 23

Chronic Obstructive Pulmonary Disease (COPD) - Products under Development by Companies 27

Chronic Obstructive Pulmonary Disease (COPD) - Products under Investigation by Universities/Institutes 40

Chronic Obstructive Pulmonary Disease (COPD) - Companies Involved in Therapeutics Development 41

Chronic Obstructive Pulmonary Disease (COPD) - Therapeutics Assessment 146

Drug Profiles 177

Chronic Obstructive Pulmonary Disease (COPD) - Dormant Projects 505

Chronic Obstructive Pulmonary Disease (COPD) - Discontinued Products 529

Chronic Obstructive Pulmonary Disease (COPD) - Product Development Milestones 536

Appendix 554

List of Tables

List of Tables

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H2 2016 32

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD) – Comparative Analysis, H2 2016 33

Number of Products under Development by Companies, H2 2016 35

Number of Products under Development by Companies, H2 2016 (Contd..1) 36

Number of Products under Development by Companies, H2 2016 (Contd..2) 37

Number of Products under Development by Companies, H2 2016 (Contd..3) 38

Number of Products under Development by Companies, H2 2016 (Contd..4) 39

Number of Products under Development by Companies, H2 2016 (Contd..5) 40

Number of Products under Development by Companies, H2 2016 (Contd..6) 41

Number of Products under Development by Companies, H2 2016 (Contd..7) 42

Number of Products under Development by Companies, H2 2016 (Contd..8) 43

Number of Products under Investigation by Universities/Institutes, H2 2016 44

Comparative Analysis by Late Stage Development, H2 2016 45

Comparative Analysis by Clinical Stage Development, H2 2016 46

Comparative Analysis by Early Stage Development, H2 2016 47

Comparative Analysis by Unknown Stage Development, H2 2016 48

Products under Development by Companies, H2 2016 49

Products under Development by Companies, H2 2016 (Contd..1) 50

Products under Development by Companies, H2 2016 (Contd..2) 51

Products under Development by Companies, H2 2016 (Contd..3) 52

Products under Development by Companies, H2 2016 (Contd..4) 53

Products under Development by Companies, H2 2016 (Contd..5) 54

Products under Development by Companies, H2 2016 (Contd..6) 55

Products under Development by Companies, H2 2016 (Contd..7) 56

Products under Development by Companies, H2 2016 (Contd..8) 57

Products under Development by Companies, H2 2016 (Contd..9) 58

Products under Development by Companies, H2 2016 (Contd..10) 59

Products under Development by Companies, H2 2016 (Contd..11) 60

Products under Development by Companies, H2 2016 (Contd..12) 61

Products under Investigation by Universities/Institutes, H2 2016 62

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by AB2 Bio Ltd., H2 2016 63

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Abeona Therapeutics, Inc. , H2 2016 64

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Ache Laboratorios Farmaceuticos S/A, H2 2016 65

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Achillion Pharmaceuticals, Inc., H2 2016 66

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Adamis Pharmaceuticals Corporation, H2 2016 67

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Advinus Therapeutics Ltd, H2 2016 68

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by AlgiPharma AS, H2 2016 69

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Allinky Biopharma, H2 2016 70

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Alteogen Inc., H2 2016 71

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Amakem NV, H2 2016 72

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Ampio Pharmaceuticals, Inc., H2 2016 73

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Angion Biomedica Corp., H2 2016 74

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Apellis Pharmaceuticals Inc, H2 2016 75

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Aridis Pharmaceuticals LLC, H2 2016 76

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Astellas Pharma Inc., H2 2016 77

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by AstraZeneca Plc, H2 2016 78

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Asubio Pharma Co., Ltd., H2 2016 79

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Axikin Pharmaceuticals, Inc., H2 2016 80

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Bayer AG, H2 2016 81

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Beech Tree Labs, Inc., H2 2016 82

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Bioneer Corporation, H2 2016 83

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Biotie Therapies Corp., H2 2016 84

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Boehringer Ingelheim GmbH, H2 2016 85

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by C4X Discovery Holdings PLC, H2 2016 86

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Carolus Therapeutics, Inc., H2 2016 87

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Cellular Biomedicine Group, Inc., H2 2016 88

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Chiesi Farmaceutici SpA, H2 2016 89

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Circassia Pharmaceuticals Plc, H2 2016 90

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by CSL Limited, H2 2016 91

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Cytokinetics, Inc., H2 2016 92

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Daiichi Sankyo Company, Limited, H2 2016 93

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Diffusion Pharmaceuticals Inc., H2 2016 94

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Domainex Limited, H2 2016 95

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Elsalys Biotech SAS, H2 2016 96

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by enGene, Inc, H2 2016 97

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Errant Gene Therapeutics, LLC, H2 2016 98

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 99

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Foresee Pharmaceuticals, LLC, H2 2016 100

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Galapagos NV, H2 2016 101

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Gilead Sciences, Inc., H2 2016 102

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by GlaxoSmithKline Plc, H2 2016 103

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Hanmi Pharmaceuticals, Co. Ltd., H2 2016 104

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by iCeutica, Inc., H2 2016 105

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by InMed Pharmaceuticals Inc., H2 2016 106

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Innate Pharma S.A., H2 2016 107

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by INVENT Pharmaceuticals, Inc., H2 2016 108

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Invion Limited, H2 2016 109

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Jiangsu Hansoh Pharmaceutical Co., Ltd., H2 2016 110

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Johnson & Johnson, H2 2016 111

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by KaloBios Pharmaceuticals, Inc., H2 2016 112

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Kissei Pharmaceutical Co., Ltd., H2 2016 113

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2016 114

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Ligand Pharmaceuticals, Inc., H2 2016 115

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Medestea Research & Production S.p.A., H2 2016 116

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Merck & Co., Inc., H2 2016 117

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Mereo Biopharma Group Plc, H2 2016 118

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Meridigen Biotech Co., Ltd., H2 2016 119

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Microbion Corporation, H2 2016 120

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Novartis AG, H2 2016 121

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Odan Laboratories Ltd., H2 2016 122

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by OPKO Health, Inc., H2 2016 123

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Orion Oyj, H2 2016 124

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Panmira Pharmaceuticals, LLC., H2 2016 125

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Pfizer Inc., H2 2016 126

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by PharmaLundensis AB, H2 2016 127

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Pharmaxis Limited, H2 2016 128

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Pila Pharma AB, H2 2016 129

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Polyphor Ltd., H2 2016 130

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Promedior, Inc., H2 2016 131

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by ProMetic Life Sciences Inc., H2 2016 132

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Proteostasis Therapeutics, Inc., H2 2016 133

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Pulmagen Therapeutics LLP, H2 2016 134

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Pulmatrix, Inc., H2 2016 135

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Quark Pharmaceuticals, Inc., H2 2016 136

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Re-Pharm Limited, H2 2016 137

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Recipharm AB, H2 2016 138

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Respira Therapeutics Inc, H2 2016 139

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Respiratorius AB, H2 2016 140

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by rEVO Biologics, Inc., H2 2016 141

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Rhizen Pharmaceuticals S.A., H2 2016 142

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by SATT North SAS, H2 2016 143

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Selvita S.A., H2 2016 144

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Seoul Pharma Co., Ltd., H2 2016 145

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Spring Bank Pharmaceuticals, Inc., H2 2016 146

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Stelic Institute & Co., Inc., H2 2016 147

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by sterna biologicals Gmbh & Co KG, H2 2016 148

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Sucampo Pharmaceuticals, Inc., H2 2016 149

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Sun Pharma Advanced Research Company Ltd., H2 2016 150

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Sunovion Pharmaceuticals Inc., H2 2016 151

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Synovo GmbH, H2 2016 152

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Syntrix Biosystems, Inc., H2 2016 153

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 154

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Teva Pharmaceutical Industries Ltd., H2 2016 155

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by TGV-Laboratories, H2 2016 156

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Therabron Therapeutics, Inc., H2 2016 157

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Theravance Biopharma, Inc., H2 2016 158

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Torrent Pharmaceuticals Limited, H2 2016 159

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by U.S. Stem Cell, Inc., H2 2016 160

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Unizyme Laboratories A/S, H2 2016 161

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Vectura Group Plc, H2 2016 162

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Verona Pharma Plc, H2 2016 163

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Vertex Pharmaceuticals Incorporated, H2 2016 164

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Yuhan Corporation, H2 2016 165

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Yungjin Pharm. Co., Ltd., H2 2016 166

Chronic Obstructive Pulmonary Disease (COPD) – Pipeline by Zambon Company S.p.A., H2 2016 167

Assessment by Monotherapy Products, H2 2016 168

Assessment by Combination Products, H2 2016 169

Number of Products by Stage and Target, H2 2016 171

Number of Products by Stage and Mechanism of Action, H2 2016 183

Number of Products by Stage and Route of Administration, H2 2016 196

Number of Products by Stage and Molecule Type, H2 2016 198

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects, H2 2016 527

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..1), H2 2016 528

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..2), H2 2016 529

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..3), H2 2016 530

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..4), H2 2016 531

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..5), H2 2016 532

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..6), H2 2016 533

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..7), H2 2016 534

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..8), H2 2016 535

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..9), H2 2016 536

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..10), H2 2016 537

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..11), H2 2016 538

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..12), H2 2016 539

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..13), H2 2016 540

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..14), H2 2016 541

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..15), H2 2016 542

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..16), H2 2016 543

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..17), H2 2016 544

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..18), H2 2016 545

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..19), H2 2016 546

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..20), H2 2016 547

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..21), H2 2016 548

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..22), H2 2016 549

Chronic Obstructive Pulmonary Disease (COPD) – Dormant Projects (Contd..23), H2 2016 550

Chronic Obstructive Pulmonary Disease (COPD) – Discontinued Products, H2 2016 551

Chronic Obstructive Pulmonary Disease (COPD) – Discontinued Products (Contd..1), H2 2016 552

Chronic Obstructive Pulmonary Disease (COPD) – Discontinued Products (Contd..2), H2 2016 553

Chronic Obstructive Pulmonary Disease (COPD) – Discontinued Products (Contd..3), H2 2016 554

Chronic Obstructive Pulmonary Disease (COPD) – Discontinued Products (Contd..4), H2 2016 555

Chronic Obstructive Pulmonary Disease (COPD) – Discontinued Products (Contd..5), H2 2016 556

Chronic Obstructive Pulmonary Disease (COPD) – Discontinued Products (Contd..6), H2 2016 557

List of Figures

List of Figures

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD), H2 2016 32

Number of Products under Development for Chronic Obstructive Pulmonary Disease (COPD) – Comparative Analysis, H2 2016 33

Number of Products under Development by Companies, H2 2016 34

Number of Products under Investigation by Universities/Institutes, H2 2016 44

Comparative Analysis by Late Stage Development, H2 2016 45

Comparative Analysis by Clinical Stage Development, H2 2016 46

Comparative Analysis by Early Stage Products, H2 2016 47

Assessment by Monotherapy Products, H2 2016 168

Assessment by Combination Products, H2 2016 169

Number of Products by Top 10 Targets, H2 2016 170

Number of Products by Stage and Top 10 Targets, H2 2016 170

Number of Products by Top 10 Mechanism of Actions, H2 2016 182

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 182

Number of Products by Top 10 Routes of Administration, H2 2016 195

Number of Products by Stage and Top 10 Routes of Administration, H2 2016 195

Number of Products by Molecule Types, H2 2016 197

Number of Products by Stage and Molecule Types, H2 2016 197

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports